Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular Tachycardia

NCT05763953 is registered in ClinicalTrials.gov with Milestone Pharmaceuticals Inc. as lead sponsor.

NCT NCT05763953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05763953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular Tachycardia
Lead sponsor
Milestone Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 11, 2023
Completion date
June 30, 2027
Enrollment
60 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal supraventricular tachycardia